Table 2.
Duration of primary series vaccine effectiveness against VOC
| VOC | Time since vaccination | No. of estimates | Pooled estimate (95% CI) | Pooled VE (%) (95% CI) |
|---|---|---|---|---|
| Against SARS-CoV-2 infection | ||||
| Alpha | 14–90 | 1 | 0.130 (0.120, 0.140) | 87.0 (86.0, 88.0) |
| 91–180 | – | – | – | |
| > 180 | – | – | – | |
| Gamma | 14–90 | 4 | 0.538 (0.470, 0.616) | 46.2 (38.4, 53.0) |
| 91–180 | 1 | 0.579 (0.535, 0.627) | 42.1 (37.3, 46.5) | |
| > 180 | – | – | – | |
| Delta | 14–90 | 5 | 0.437 (0.309, 0.618) | 56.3 (38.2, 69.1) |
| 91–180 | 5 | 0.778 (0.637, 0.951) | 22.2 (4.9, 36.3) | |
| > 180 | 4 | 0.791 (0.681, 0.919) | 20.9 (8.1, 31.9) | |
| Omicron | 14–90 | 3 | 0.659 (0.572, 0.760) | 34.1 (24.0, 42.8) |
| 91–180 | – | – | – | |
| > 180 | 3 | 0.928 (0.883, 0.977) | 7.2 (2.3, 11.7) | |
| Against severe COVID-19 | ||||
| Alpha | 14–90 | 2 | 0.100 (0.085, 0.117) | 90.0 (88.3, 91.5) |
| 91–180 | – | – | – | |
| > 180 | – | – | – | |
| Gamma | 14–90 | 3 | 0.225 (0.115, 0.439) | 77.5 (56.1, 88.5) |
| 91–180 | 1 | 0.230 (0.209, 0.253) | 77.0 (74.7, 79.1) | |
| > 180 | – | – | – | |
| Delta | 14–90 | 7 | 0.213 (0.112, 0.404) | 78.7 (59.6, 88.8) |
| 91–180 | 7 | 0.438 (0.320, 0.600) | 56.2 (40.0, 68.0) | |
| > 180 | 4 | 0.432 (0.290, 0.643) | 56.8 (35.7, 71.0) | |
| Omicron | 14–90 | 3 | 0.401 (0.299, 0.539) | 59.9 (46.1, 70.1) |
| 91–180 | – | – | – | |
| > 180 | 3 | 0.355 (0.281, 0.448) | 64.5 (55.2, 71.9) | |